+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 100Years
All Genders
ID05815173

Phase III Study of Ladarixin and Sotorasib for Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Led by NYU Langone Health · Updated on 2025-12-30

40

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of ladarixin and sotorasib in patients with advanced non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation. This phase III open-label study aims to determine the best dose of ladarixin to use with sotorasib and to assess how long patients live without their cancer progressing. The study focuses on patients who have not previously been treated with KRAS G12C inhibitors and have experienced progression after prior therapies. Participants will receive sotorasib once daily at an approved dose of 960 mg and ladarixin twice daily. In the phase I part, ladarixin dosing will be carefully increased to find the recommended dose for phase II, with close monitoring for side effects during 21-day treatment cycles. Phase II will use the recommended dose of ladarixin alongside sotorasib over similar 21-day cycles. All patients receive the same combination treatment. During the study, participants will undergo various assessments including laboratory tests to monitor blood counts and organ function, imaging scans to evaluate tumor response, and tracking of any side effects. The primary outcomes include measuring dose-limiting toxicities in the first treatment cycle and progression-free survival up to 36 months. Safety and treatment responses will be followed closely, with survival and adverse events monitored throughout the study duration.

CONDITIONS

Brief Title

Ladarixin With Sotorasib in Advanced NSCLC

Research Team

S

Salman Punekar, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here